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 Summary of research 
 
Mortality and health aspects associated with long term use of opioid maintenance 
treatment (OMT) are insufficiently researched. The first study investigated mortality 
prior to, during and after the Norwegian OMT programme. A national OMT register 
was established based on the electronic record system in OMT centres in Norway. 
The register contained a total observation period of seven years, from January 1997 
to December 2003. Based on national security numbers, these data were cross-
linked with the Norwegian national death register, consisting of all Norwegian death 
certificates. The death certificates include one principal cause of death, and up to 
four underlying causes (ICD 10 codes). Only the principal cause of death was used. 
There was a significant overall reduction in mortality risk between pre-treatment and 
in-treatment groups (hazard ratio 0.5, P = 0.001). The post-treatment group as a 
whole was not significantly different from the pre-treatment group with regards to 
mortality; however, a tendency toward gender differences was observed. Following 
treatment, males had significantly higher mortality compared to the pre-treatment 
levels. The post-treatment females had a non-significant tendency toward reduced 
mortality. A significant overall reduction in mortality risk between the pre-treatment 
and the intention-to-treat individuals (hazard ratio of 0.6, P = 0.004) was identified.  
Risk of overdose death was significantly reduced with OMT, both for the in-treatment 
group separately and in intention-to-treat analysis. 
 
We then investigated the prevalence of corrected QT (QTc) interval prolongation in 
OMT. Many studies have pointed to a relation between methadone and QTc 
prolongation. This is associated with a type of cardiac arrhythmia known as torsades 
des points (TdP) that can lead to syncope and in worst case sudden death. Our aim 
was to assess the prevalence of QTc prolongation over 500 msec (generally 
considered the threshold for TdP development), to compare methadone and 
buprenorphine, investigate a potential dose-dependent association and possible risk 
factors for prolonged QTc interval. 
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In a cross-sectional study, we recorded electrocardiographies (ECGs) on 200 OMT 
patients in Oslo. 173 of these were on methadone, the rest on buprenorphine.  
The ECGs were assessed by a senior cardiologist, blinded for all patient details.  
Of the 173 patients on methadone, eight were found to have QTc interval above 500 
msec. These were all on doses of 120 mg or more per day. None of the 
buprenorphine patients exhibited QTc prolongation. A dose-dependent association 
was found between methadone dose and the length of the QTc interval. There was 
no association detected in the analyses between age, gender or time in treatment 
and QTc prolongation. 
The clinical relevance of QTc prolongation and whether deaths in OMT could 
potentially be attributed to QTc prolongation and ventricular arrhythmia was 
investigated. The data from the first cross-register study was examined and the 
stated causes of death for patients in treatment analysed. 90 deaths had occurred 
among the 2382 patients with 6450 total years in OMT. Only four could possibly be 
attributed to ventricular arrhythmia. Thus, the maximum mortality rate potentially 
attributable to QTc prolongation was 0.06 deaths per 100 patient years in OMT. 
Additionally, only one death among 3850 OMT initiations occurred within the first 
month of treatment. 
Finally, the eight patients previously found to have prolonged QTc intervals above 
500 msec were offered further cardiac investigations and management.  
The investigations included a new ECG at rest, exercise ECG, 24 hours ECG (Holter) 
and genetic testing for the five most common long QT syndrome (LQTS) mutations. 
Seven patients accepted genetic testing. One of these later dropped out of OMT.  
Six patients attended the cardiac outpatient clinic. The QTc intervals fluctuated widely 
over 24 hours and during exercise. Two were heterozygous carriers of mutations in 
LQTS1 and LQTS2 genes, respectively. Both had previous histories of cardiac 
symptoms, but had never been under cardiac investigations prior to the study.  
One had already switched to buprenorphine and started on protective beta-blocker. 
None of the remaining five patients, including the women with the LQTS2 mutation, 
wanted to switch to buprenorphine or take other cardiac protective measures. Safe 
cardiac management of methadone patients found to have QTc prolongation proved 
very difficult. 
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Norsk sammendrag 
 
Dødelighet og helseproblemer knyttet til legemiddelassistert rehabilitering (LAR) er 
utilstrekkelig forsket på. I det første studiet undersøkte vi dødelighet knyttet til 
perioden før, under og etter LAR behandling. Et norsk LAR register ble etablert og 
inneholdt informasjon om alle som hadde søkt LAR i Norge over en syv års periode, 
fra januar 1997 til desember 2003. Ved bruk av personnummer ble dette registeret 
krysset med det norske dødsårsaksregisteret til Statistisk sentralbyrå (SSB).  
Kun hoveddødsårsak ble benyttet.  
En signifikant totalreduksjon i dødelighet ble funnet under behandling, sammenlignet 
med før LAR. På totalgruppenivå var det ingen dødelighetsforskjell mellom før- og 
etter-LAR gruppene, mens en tendens til kjønnsforskjell ble funnet. Etter avsluttet 
behandling hadde menn en signifikant økt dødelighet sammenlignet med før LAR, 
mens kvinner hadde en ikke-signifikant tendens til lavere dødelighet. En signifikant 
nedgang i dødelighet ble funnet mellom før-LAR og intensjon-om-å-behandle-
gruppene. Risiko for overdosedød ble redusert med LAR, både for de i behandling og 
for intensjon-om-å-behandle-gruppen. 
Vi undersøkte også forekomsten av korrigert QT (QTc) forlengelse i LAR. Mange 
studier har vist til en sammenheng mellom metadon og QTc forlengelse. Dette 
tilknyttes en type hjertearytmi kjent som torsades des pointes (TdP), som kan lede til 
synkope og i verste fall brå død. Vårt mål var å undersøke forekomsten av QTc 
forlengelse over 500 millisekunder (ofte antatt å være terskel for TdP utvikling),  
å sammenligne metadon og buprenorfin, undersøke en potensiell dose-avhengighet, 
samt å kartlegge risikofaktorer for forlenget QTc intervall. 
I vår tverrsnittsstudie tok vi elektrokardiografi (EKG) av 200 LAR pasienter i Oslo. 173 
av disse sto på metadon, resten på buprenorfin. EKG'ene ble tolket av en kardiolog, 
uvitende om alle pasientdetaljer. Av de 173 metadonpasientene ble åtte identifisert 
med QTc forlengelse over 500 millisekunder. Alle disse hadde metadondose på 120 
mg eller mer per dag. Ingen av buprenorfin-pasientene hadde QTc forlengelse. Et 
dose-avhengig forhold ble funnet mellom metadondose og lengden av QTc 
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intervallet. Det ble ikke funnet noen sammenheng mellom alder, kjønn eller tid i LAR 
og lengden på QTc intervallet. 
Den kliniske relevansen av QTc forlengelse og hvorvidt dødsfall i LAR potensielt 
kunne tilskrives QTc forlengelse og ventrikulær arytmi ble undersøkt. Data fra det 
foregående kryss-registerstudiet ble nøye gjennomgått og dødsårsakene for 
pasienter i behandling analysert. 90 dødsfall hadde forekommet blant de 2382 LAR 
pasientene med til sammen 6450 år i LAR. Kun fire av disse kunne muligens 
tilskrives ventrikulær arytmi. Den maksimale dødeligheten som potentielt kunne 
tilskrives QTc forlengelse var 0.06 dødsfall per 100 personår i LAR. Av 3850 
oppstarter i LAR forekom det kun ett dødsfall under den første behandlingsmåneden. 
De åtte pasientene med QTc forlengelse over 500 millisekunder i tverrsnittsstudiet 
ble tilbudt videre hjerteutredning og behandling. Undersøkelsene inkluderte et nytt 
hvileEKG, belastningsEKG, 24 timers EKG (Holter) og genetisk test for de fem mest 
vanlige lang QT syndrom (LQTS) mutasjonene. Syv pasienter ønsket genetisk 
testing. En av disse droppet etterpå ut av LAR. Seks pasienter deltok i videre 
hjerteutredning. Alle hadde store døgnvariasjoner i QTc intervallet og også under 
belastning. To pasienter var heterozygote bærere av LQTS mutasjoner, henholdsvis i 
LQTS1 og LQTS2 gener. Begge hadde i anamnesen tidligere opplevd 
hjertesymptomer, men de hadde ikke blitt utredet for dette før deltagelse i studiet.  
En av dem hadde allerede byttet fra metadon til buprenorfin og startet under studiet 
på en beskyttende beta-blokker. Ingen av de resterende fem pasientene, inkludert 
kvinnen med LQTS2 mutasjon, ønsket overgang til buprenorfin eller andre 
hjertebeskyttende tiltak. Trygg hjertebehandling av metadonpasienter med QTc 
forlengelse viste seg svært utfordrende.     
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Introduction  
 
Opioid dependence: an increasing public concern 
According to The world health organisation (WHO), there has been a global increase 
in the production, transportation and consumption of opioids, mainly heroin over the 
years. Heroin use has become increasingly common in North America and Europe 
since the 1960s.1 From 1985 until today the worldwide production of heroin has more 
than doubled, or even tripled. Globally, it is estimated that 13.5 million people take 
opioids and of these 9.2 million use heroin.  
In European countries, the average prevalence of problem opioid use in the countries 
providing data is estimated to be between 3.6 and 4.6 cases per 1 000 of the 
population aged 15–64. Assuming that this reflects Europe as a whole, it implies that 
about 1.4 million (1.2–1.5 million) people were problem opioid users in the EU and 
Norway in 2007.2 
 
Mortality in opioid dependence 
Mortality among untreated opioid dependants is internationally estimated with wide 
variations; between 1 to 4 per 100 person years.3-6 Heroin injectors who regularly 
consume large amounts of different drugs, face a risk of death which may be 20 to 30 
times higher than non-drug users in the same age range.1 Relative risk and odds 
ratio are calculated in relation to baseline mortality in the general population, which 
depends upon living standards and social conditions. As these vary greatly among 
different populations worldwide, variations in mortality levels across different groups 
of illicit drug users are subsequently the result. The majority of deaths among opiate 
dependents are reported to be overdose related.7-9 Other common causes of death in 
this group are trauma, including suicide and murder, as well as somatic causes such 
as blood-borne infections.10 The number of overdoses will depend on gender, age, 
type of drug and drug administration, personality, general health status and the 
availability of treatment within the group. The extent to which drug treatment is 
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provided and easily accessible, will substantially influence the rates of drug-related 
mortality in these populations.10 
 
Treatment strategies for opioid dependence 
In theory there are two main types of treatment for opioid dependence; abstinence-
oriented therapy and substitution therapy. There are numerous different approaches 
within abstinence-oriented treatment and these cover both institutionalised and  
out-patient based therapy. It is not within the scope of this thesis to discuss the many 
varieties currently used, but in summary as the phrase abstinence-oriented suggests, 
they all aim for a drug-free state. To reach this goal, the patient has to go from a 
drug-using to an abstinent state. In the period following opioid detoxification, the 
rates of fatal overdoses appear increased. This is assumed to be linked to loss of 
tolerance and the subsequent unpredictability of resumed heroin use.11  
A recently published study by Ravndal and Amundsen pointed to an unadjusted 
excess overdose mortality, with a rate ratio (RR) of 15.7 (95% confidence interval 
(CI) of 5.3-38.3) during the first 4 weeks after discharge from inpatient facilities with 
various abstinence-oriented treatment approaches for opioid dependents.12 Research 
has also highlighted the increased risk of overdose death in this population after 
prison release. One study among HIV positive injecting drug users found a relative 
risk of overdose during the first two weeks after release of 7.7 when compared to the 
next 10 weeks.13 A study of the United States prison population found that during the 
first two weeks following release, the risk of any mortality was 12.7 (CI 9.2-17.4) 
times that of other state residents. The risk of death from overdose was particularly 
high; 129 (CI 89-186). 14  
A way of protecting individuals against the increased risk of opioid overdose 
detoxification is by using an opioid antagonist. Naloxone is a short-acting, non-
selective opioid receptor antagonist. As the oral bioavailability is low, the route of 
effective administration is by intravenous or intramuscular injection. Due to the onset 
of action within minutes, this is the drug used for immediate opioid overdose 
reversal.15 Naltrexone is another opioid antagonist, which is orally effective and 
longer-acting. A Cochrane review suggested that although oral naltrexone reduced 
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heroin use more that placebo and psychosocial counselling, it was not beneficial on 
heroin relapse or treatment retention rates.16 Over the last decade, sustained-release 
naltrexone has been investigated in larger clinical trials. The results are so far 
promising, but the amount of evidence of its effectiveness is still limited.17;18  
 
Opioid maintenance treatment for opioid dependence 
The alternative to abstinence-oriented therapy is substitution treatment. Methadone 
was first synthesised in Germany in 1937 and during World War II it became an 
important analgesic, as the supply of traditional morphine was short.19 It is a synthetic 
opioid agonist that binds to the opioid µ-receptor. Vincent P Dole and Marie 
Nyswander conducted the first studies in the 1960s, treating heroin addicted patients 
with methadone. The treatment was intended to replace the use of illicit opioids, 
mainly heroin, with this long acting agonist, without giving rise to intoxication.  
They emphasized that methadone could only prevent symptoms of withdrawal and 
craving; treatment with methadone alone would not restore the life and relations the 
patient had prior to the heroin addiction and it was only a mean to facilitate this 
rehabilitation.20 Methadone maintenance treatment (MMT) is today the most 
commonly used treatment for opiate dependence worldwide, and its effectiveness on 
attrition and relapse prevention has been demonstrated in many studies.21-23 
In addition to methadone, buprenorphine is the other most commonly used OMT 
drug. This is a synthetic opioid that also binds to the µ-opioid receptor. It is a partial 
agonist, which is known to reach a ceiling effect and is assumed to be less likely to 
produce intoxication compared to methadone. 24 Due to potential misuse and 
injection of buprenorphine tablets, a preparation that contains both buprenorphine 
and naloxone is now available.25 Although all opioids in theory may be suitable as 
maintenance drugs, currently oral slow-release morphine, codeine and heroin are the 
other drugs widely used for opioid maintenance treatment purposes.18 
In Europe many opioid users are enrolled in programmes providing long-term care. 
This is reflected in an increasing proportion of primary opioid users among drug users 
already in treatment. The total number of clients receiving substitution treatment in 
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the EU, Croatia and Norway was estimated to be about 650 000 in 2007, up from 560 
000 in 2005 and 500 000 in 2003.  
Opioid maintenance treatment (OMT) is generally considered to be the most 
important harm-reducing measure in opioid dependence,26;27 and it is often stated 
that “OMT saves lives”.28;29 Although there is accumulating evidence to support this, 
the underlying research contains several limitations. This particularly relates to the 
level of risk reduction, which is highly important both in treatment policy; balancing 
the need for control with the need for availability and the management of individual 
patients. 
 
Mortality in opioid maintenance treatment 
Mortality has been included in the outcome measures of some randomized controlled 
trials (RCTs) with short follow-up periods up to 20 weeks, with little or no significant 
mortality reducing effects found.30;31 Study designs with large samples and long-term 
follow-up periods are needed, but difficult to apply in RCTs, in order to thoroughly 
investigate the potential mortality reducing effects.32 A systematic review published in 
2005 by Amato and colleges concluded that OMT did not exhibit a significantly 
proven reduction in mortality.3  
Nonetheless, the results from OMT research have been divergent on the issue.  
A Swedish clinical trial comparing buprenorphine maintenance to medically 
supervised buprenorphine withdrawal, observed a statistically significant reduction in 
mortality rates favouring buprenorphine maintenance.33 The group stabilised on 
buprenorphine would presumably experience less abstinence and also receive some 
protection against overdose from the drug itself. The conclusions from this clinical 
trial were further limited by a rather small study size. In 1981, Gunne randomly 
assigned a group of intravenous heroin abusers to either methadone maintenance 
treatment (n=17) or no treatment (n=17) and found marked differences in mortality.28 
After a 2 years follow-up period, none of the MMT patients had died, whereas two 
patients died in the control group. Of the MMT patients, 12 were drug-free and the 
remaining five had recurrent drug problems. Among the controls, one was drug-free, 
12 were continuously abusing heroin and two were imprisoned. Notably, that study 
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was performed in a time of policy conflict in Sweden and the group denied treatment 
were left in a vulnerable situation. This highlights the worrying ethical aspects of an 
RCT design in this setting.   
The mortality-reducing effects of OMT are primarily established through observational 
studies. These often exclude dropouts, sometimes lack clear selection criteria for 
treatment or might be seen as local area studies with low generalisation.4;34;35 
Consequently, the findings are mostly applicable to those selected by the specific 
treatment unit and maintained in the actual treatment studied. Even well designed 
cohort studies face challenges with persons lost to follow-up, a commonly recognised 
problem in the research field of drug addiction.36;37 Although large, long-term case-
control studies would be desirable, the ethical considerations attached would not 
permit such an approach. 
Programme characteristics such as treatment approach, inclusion and exclusion 
criteria may vary. Comparison of effect of OMT programmes in various countries or 
regions can therefore be challenging and indeed highlight the effects on mortality of 
different criteria for entering treatment. For example, a study from the capital of 
Sweden found no opiate overdose deaths in their OMT population. The Stockholm 
programme did not, however, include polydrug users and excluded all patients with 
concurrent use of drugs.38 The in-treatment effects of such a programme may be 
favourable, but the external validity limited. 
Today increasing numbers of people are being treated with OMT worldwide and 
larger studies to quantify the treatment effect on mortality is clearly called for. It is 
likewise important to investigate the mortality risk associated with leaving OMT. 
 
Common effects and side-effects of opioids  
Opioid receptors are found in neurones and are spread throughout the central 
nervous system (CNS).39 The opioid receptors are also found in many other cells in 
the central and peripheral nervous systems. There are three main types of opioid 
receptors.40 The µ-receptors are thought to be responsible for most of analgesic 
effects of opioids and are also linked to some major unwanted effects, such as 
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dependence, sedation and respiratory depression. The δ-receptors are probably 
more important in the periphery, but may also contribute to analgesia.  
The К-receptors contribute to analgesia at the spinal level, but produce relatively few 
unwanted effects and do not contribute to dependence.  
Depending on the physiological response from receptor binding, the opioids are 
divided into pure agonists, like methadone, and partial agonists/antagonists, like 
buprenorphine. Pure agonists will give maximal biological response, whilst partial 
agonists will have less effect. Although the various opioids differ in terms of potency, 
pharmacokinetics and effect on various organ systems, they generally share some 
common properties. When used over a longer period there is a gradual tolerance 
development, in which the effect of the opioid decreases with time and higher doses 
are needed to reach the same level of effect. The use of higher doses is 
accompanied by increased dose-dependent side-effects. Acute discontinuation of the 
opioid after 14 days use or more will often lead to withdrawal symptoms such as 
anxiety, hyperventilation, sweating, dilated pupils and increased pain. Later on more 
severe symptoms like tachycardia, tremor, nausea, vomiting and diarrhoea may 
occur. 
The therapeutic action of opioids is mainly analgesia, by which they have undisputed 
effect.40 This is commonly their sole indication for use in medicine today. They have 
also been used therapeutically to suppress coughing, produce sleep and euphoria 
and prevent diarrhoea. Due to the spread of opioid receptors, opioids affect the 
various systems of the body and give rise to some common side-effects. All opioids 
reduce the sensitivity for carbon monoxide in the respiratory centre of the CNS, 
leading to respiratory depression. Gastrointestinal symptoms are also common, and 
include nausea, vomiting and constipation. Dizziness, sedation, unsteadiness and 
confusion occur at higher doses and are most often seen among the elderly. In the 
cardiovascular system, peripheral vasodilatation and inhibition of baroreceptor reflex 
leading to hypotension may result. Opioids release histamine from mast cells, by an 
action unrelated to opioid receptors. This histamine release can cause urticaria and 
itching of the skin, as well as bronchoconstriction and hypotension. Endocrine effects 
include increased sweating, as well as inhibition of secretion of luteinizing hormone 
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(LH) over time, leading to loss of ovulation and menstrual cycle in women and 
reduced testosterone production with low libido and erectile dysfunction in men. 
In opioid maintenance treatment, the dose is slowly increased and then maintained at 
a steady level in which the patient can function optimally, avoiding both withdrawal 
symptoms and intoxication. Most patients who start on OMT are already opioid 
dependent and have developed opioid tolerance. Side-effects may still occur at the 
beginning of OMT, particularly sedation, nausea and constipation. Sweating and 
hormonal disturbances may rarely persist and require addressing. Usually the  
side-effects are minor compared to those of heroin addiction and most will disappear 
with time. However, when potentially harmful adverse effects of OMT are described, 
there is a cause for concern. Prolongation of the corrected QT (QTc) interval has 
received increased attention over the last decades and has been associated with 
some particular types of opioids, including methadone. 
 
QTc interval prolongation and methadone 
The electrical discharge of a normal cardiac cycle starts in a special area of the right 
atrium called the sinoatrial node (SAN).41 Depolarization then spreads throughout the 
atrial muscle fibres. A delay occurs when the depolarization spreads through another 
special area in the atrium called the atrioventricular node (AVN). From there, the 
electrical discharge travels very rapidly down specialised conduction tissue; first a 
single pathway, the bundle of His, which then divides in the septum between the 
ventricles into the right and left bundle branches. Within the mass of ventricular 
muscle, conduction spreads somewhat more slowly, through specialised tissue called 
Purkinje fibres. This pattern is repeated for every cardiac cycle.  
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Figure 1. The anatomy of the heart with a normal cardiac conduction system 
 
 
 
The electrical changes that occur during cardiac contraction can be detected by 
electrodes attached to the surface of the body when recording an electrocardiogram 
(ECG). The muscle mass of the atria is small compared with that of the ventricles, 
and the accompanying electrical changes is therefore small. On the ECG the atrial 
contraction is called the P wave. There is a large deflection on the ECG when the 
ventricles are depolarised and this forms the QRS complex. The T wave of the ECG 
is associated with the return of the ventricular mass to its resting electrical state 
(repolarisation).  
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Figure 2. Anatomy of the heart and appearance of a normal ECG 
 
 
 
 
The QT interval is measured from the beginning of the Q-wave to the end of the  
T wave.41 The QT interval represents the duration of activation and recovery of the 
ventricular muscles. This duration is reciprocal to the pulse and is measured in 
milliseconds (msec). Under normal conditions, this should be less than 450 msec 
when corrected for heart rate (QTc interval). Prolongation of the QTc interval is 
characterised by abnormal T-wave morphology seen on ECG and is associated with 
torsades de pointes (TdP).42 In most cases TdP is self-terminating and causes a 
quick syncopal episode. If the TdP is more persistent and the rhythm does not 
spontaneously return to normal, ventricular fibrillation occasionally leading to cardiac 
arrest and sudden death can result. TdP is rarely associated with a QTc interval of 
less than 500 msec and this is generally considered the threshold for the risk of TdP 
development.43 
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Figure 3. Torsades de pointes (TdP) 
 
 
 
Image shows: A premature ventricular beat is followed by a pause and a subsequent 
supraventricular beat. Then a premature ventricular beat appeares, followed by an 
episode of polymorphic ventricular tachycardia showing a peculiar 
electrocardiographic pattern characterised by a continuous twisting in QRS axis 
around an imaginary baseline ("torsades de pointes" - TdP). 
 
Drug-induced QTc prolongation is caused mainly by blockade of the slow component 
of the delayed rectifier potassium (K+) current (IKr), a major repolarisation current in 
the heart. The IKr blockers, such as methadone, increase the dispersion in 
repolarisation. They often have a so-called reverse frequency-dependent effect on 
the QTc interval, in which the degree of prolongation is more prominent during slow 
heart rates.44 In medical practice, this is a well-recognised adverse effect of certain 
drugs,45;46 including anti-psychotics and anti-depressants.47;48 The finding of an 
association between long-term use of opioid agonists and prolongation of the QTc 
interval was first demonstrated during maintenance treatment with levomethadyl 
hydrochloride acetate (LAAM), which was later redrawn from the market.49 
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Early studies reported an association between the use of methadone and QTc 
prolongation.50-52 Several cross-sectional studies have since confirmed this 
association.53-55 Ehret et al compared the electrocardiography (ECG) recordings of 
drug users on methadone with those of drug users not on methadone in a tertiary 
care hospital.56 Of the MMT patients, QTc prolongation of 500 msec or more was 
detected in 16.2 %. No evidence of QTc prolongation was identified among those not 
receiving methadone. Wedam et al conducted a large randomized, controlled trial 
comparing the QTc effects of methadone, levomethadyl acetate (LAAM) and 
buprenorphine.57 They found that the LAAM and methadone groups were 
significantly more likely to have a QTc greater than 470 msec (men) or 490 msec 
(women) or an increase from baseline in QTc greater than 60 msec.  
Although several studies have demonstrated a dose-dependent relationship between 
methadone dose and QTc interval,56;58;59 other researchers have not detected this 
effect. Peles et al found no correlation between QTc prolongation and methadone 
dose or serum levels.55 Martell et al found significant increases in the QTc interval 
after initiation of methadone treatment, but these were unrelated to the amount of 
methadone used.51 In their analysis of the mechanism of opioid influence on cardiac 
function, Katchman et al suggested that morphine and codeine had the largest safety 
margin,60 while other authors have advocated the great safety of buprenorphine.61;62 
Today the association between methadone and QTc prolongation is well-established. 
However, there has been disagreement about whether a dose-dependent association 
exists. Furthermore, it has remained unclear whether time in treatment, gender or 
age has any influence on the QTc interval. 
Both torsades de pointes and cardiac fibrillation have occasionally been reported 
among methadone patients.62-65 A Danish cross-sectional study by Fanoe et al found 
a dose-response association between methadone and the length of the QTc interval, 
with increased methadone dose associated with a higher frequency of reported 
syncope.66 After conducting a prospective evaluation of patients with sudden death in 
the community, Chugh and associates pointed toward an association between the 
use of methadone at therapeutic levels and the occurrence of sudden cardiac 
death.67 A review of methadone-related adverse events reported to the Food and 
Drug Administration (FDA) between 1969 and 2002 identified 59 cases involving QT 
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prolongation or TdP. Of these, 28 resulted in hospitalisation: 5 of the 59 cases 
resulted in death.68 Despite these studies, the clinical relevance and, importantly, 
whether there is mortality attributable to QTc prolongation in OMT have not been 
clearly established. 
There are often multiple contributing factors to drug-induced QTc prolongation and 
ventricular arrhythmia, including hepatic cytochrome P450 inhibitors, structural heart 
disease and hypokalemia, as well as genetic predisposition.69 These risk factors are 
often poorly identified among OMT patients before treatment with methadone is 
initiated. Despite extensive research on both congenital and acquired long QTc 
interval, to our knowledge, no previous study has specifically investigated whether 
congenital long QT syndrome (LQTS) mutation may pre-exist in patients on 
methadone maintenance treatment with prolonged QTc interval. 
 
Congenital causes of QTc interval prolongation 
Three major genes were identified as involved in congenital long QT syndrome 
(LQTS) as early as in 1995-96.70 Currently, mutations in eleven different genes 
located in seven different chromosomes have been identified. The eleven genes 
code for subunits of various ion channels (potassium, calcium and sodium) and a 
structural anchoring protein. This forms the basis of the eleven known subtypes of 
LQTS (LQTS1-11), but most of the identified mutations occur in LQTS1, LQTS2 and 
LQTS3 genes.71 Congenital long QT syndrome has both an autosomal dominant and 
a recessive trait of inheritance. When LQTS follows the dominant mode, it is 
commonly known as Romano-Ward syndrome. The recessive pattern is often 
referred to as Jervell and Lange-Nielsen syndrome and is characterised by a more 
severe phenotype and accompanied by congenital deafness.72  
A recent study from Norway investigated the prevalence of LQTS mutations in the 
Norwegian population.73 The researchers tested for mutations in the KCNQ1, HERG, 
SCN5A, minK and MiRP1 genes, which all codes for subunits of cardiac ion 
channels. By performing cascade screening of 505 relatives of index patients with 
molecularly defined LQTS, they identified 251 mutation carriers. The observed 
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penetrance was 41 %. They estimated that the prevalence in Norway of 
heterozygous mutation carriers for the five genes could be somewhere between 
1/100 and 1/300.73   
The treatment of congenital LQTS has followed three classical modalities: beta-
adrenergic blocking agents (beta-blockers), elective pacing (pacemakers) and left 
cervicothoracic sympathetic ganglionectomy.71 Beta-blockers have been the standard 
therapeutic and preventative therapy of LQTS and are effective in about 60-70 % of 
patients in all age groups.74 Pacemaker should be considered an adjunct to beta-
blockers when there is evidence of pause or bradycardia-dependent arrhythmia and 
symptomatic bradycardia induced by beta-blocker therapy.75 Left cardiac sympathetic 
denervation (ganglionectomy) is considered for LQTS patients suffering from cardiac 
events, despite treatment with beta-blockers, and in patients who experience 
arrhythmia storms with an implantable cardioverter-defibrillator (ICD).76 An ICD will 
not prevent the precipitation of TdP, but will prevent sudden cardiac death when TdP 
persists or generate ventricular fibrillation. It has been used successfully when 
therapy with the classical modalities has failed.71   
Both congenital (LQTS) and acquired prolongation of the QTc interval occur in all 
races and across all ethnic groups.77 It is vital for patients with LQTS to avoid all 
drugs associated with QTc prolongation, which could increase the cardiac risk 
further.71 Brink et al found that a QTc interval greater than 500 msec was associated 
with a 4-fold increased risk of syncope or sudden death in LQTS patients.78 However, 
congenital LQTS is often an undetected condition. More specifically, if the LQTS 
mutation has previously been silent or undetected for other reasons, there is indeed 
a risk that the patient may be started on a QTc prolonging drug, such as methadone. 
Once identified, these patients should therefore always be provided with an updated 
list of potentially harmful drugs that must be avoided.79  
 
Opioid maintenance treatment in Norway and research setting 
In Norway, opioid maintenance treatment (OMT) was established by the government 
as a national system. The programme was designed to reach the population of 
severely addicted heroin users not benefiting from other types of treatment and was 
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first made nationally available in 1998.80 At the time of our research one of the 
inclusion criteria for OMT was “several years of addiction dominated by opioid 
dependence”, verified prior to treatment. Additionally, it was also a requirement that 
the patient had made several failed attempts at abstinence-oriented therapy forms, 
prior to entering OMT. There was a 25 year age limit for inclusion, although 
exceptions were made. Persons with severe somatic or psychiatric co-morbidity were 
given priority. Treatment was based on cooperation between the social services, 
general practitioners (GPs) and specialised OMT centres. 
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Objectives 
 
Overall research aims 
There were two overall aims in this research. The first was to evaluate changes in 
mortality rate before, during and after opioid maintenance treatment (OMT) in 
association with overdose and non-overdose as causes of death. This is dealt with in 
paper 1. The second overall aim was to investigate QTc prolongation in OMT, with 
regards to prevalence, clinical relevance and manifestation, and presence of 
contributing risk factors, including genetic predisposition. This aim is approached in 
paper 2 and 3. 
 
 
Objectives for each paper 
Paper 1 
Mortality prior to, during and after opioid maintenance treatment (OMT):  
A national prospective cross-registry study 
Research objectives: 
1. To assess differences in mortality rates prior to, during and after OMT. 
2. To evaluate mortality reductions in an intention-to-treat perspective. 
3. To examine the distribution of drug overdose versus non-overdose  
as cause of death. 
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Paper 2 
Prevalence and clinical relevance of corrected QT interval prolongation during 
methadone and buprenorphine treatment: A mortality assessment study 
Research objectives: 
1. To investigate the prevalence of QTc prolongation among opioid maintenance 
treatment (OMT) patients in Oslo. 
2. To assess any relation between QTc prolongation and type of agonist 
(methadone and buprenorphine), dose, gender and length of treatment. 
3. To estimate the extent to which deaths occurring in the Norwegian OMT 
programme might be attributed to QTc prolongation. 
 
 
Paper 3 
Opioid maintenance patients with QTc prolongation:  
Congenital long QT syndrome mutation may be a contributing risk factor 
Research objectives: 
1. To describe the findings of past medical history, drug and family history, 
focusing in particular on cardiac symptoms and other risk factors for  
QTc prolongation. 
2. To conduct genetic testing for LQTS mutations among OMT patients with  
QTc interval > 500 msec. 
3. To discuss in detail the findings from cardiac investigation and management  
of OMT patients found to have QTc prolongation.  
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Material and methods 
 
Cross-register mortality study (Paper 1) 
 
Sample 
All opioid-dependent people who applied for and were accepted for OMT in Norway 
between 1 January 1997 and 31 December 2003 were included in the data for this 
study. This made a total of 3789 individuals with a total observation time of up to 
seven years. The design was a prospective cohort, where persons were included as 
they applied for OMT, resulting in individual and varying observation times; from 
inclusion until 31.12.2003, which was the time set for examination of mortality. 
At the time of our mortality study, there was estimated to be between 8200 and 
12500 injecting opiate addicts in Norway.81 Of the patients accepted for OMT,  
90-95 % were intravenous drug users. Buprenorphine was registered as a 
therapeutic OMT drug in 2001 and was used by 23% by the end of 2003. At the start 
of the observation period all patients were on methadone and in total during the 
whole period more than 9 out of 10 patients used methadone, according to the 
annual Norwegian OMT evaluations.82The average dosing of methadone and 
buprenorphine was 112 mg and 20 mg, respectively in 2005.80;82;83 
 
Data collection 
The sample was divided into pre-treatment (applicants qualifying for OMT, but prior to 
initiation of treatment = waiting list), in-treatment (in OMT) and post-treatment (after 
termination of OMT). A national OMT register including national ID numbers was 
established based on the electronic record system in each OMT centre. Each centre 
provided lists of all persons who had applied for, entered and left OMT during the 
observation period. These lists were sent to Statistics Norway and information on the 
date and cause(s) of any deaths were attached to the data files. Statistics Norway 
(SSB) is responsible for a national mortality register, based on all Norwegian death 
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certificates. The merging of data registers was performed towards the end of 2005. 
Thus, all deaths in the observation period (through to end of 2003) are included in the 
register. 
 
Measures and definitions 
All death certificates registered with Statistics Norway are completed by a medical 
doctor after examination of the deceased. In about one-third of cases, additional 
information as a result of autopsy is included.84 Death certificates include one 
principal cause of death, and up to four underlying causes (ICD 10 codes).84;85  
Only the principal cause of death was used. Acute intoxications resulting in death 
from all substances were combined in an “overdose” category. These comprised ICD 
10 codes F11.0, F19.0, X42.0 and X44.0 diagnoses. The non-overdose groups 
included both somatic and sudden/violent deaths (such as suicide, traffic accidents 
and homicide).  
Some subjects included in the study (167 individuals) underwent several treatment 
periods. In-treatment refers in this study to the actual number of days in treatment 
(sum of days in treatment, excluding days after or between treatment periods).  
Post-treatment is the number of days out of treatment both between and following 
treatment periods within the study period. If subjects had several application dates, 
the first date was chosen.  
The register initially contained some individuals that for varying reasons did not start 
treatment. Some did not fulfil the criteria of opioid dependence. Others chose long 
term drug free residential treatment and some chose not to start for other reasons. 
These subjects had application dates, but no treatment initiation within one year. 
The applications were all re-examined and verification of the application status 
confirmed. Subjects who were ineligible or withdrew their application for OMT 
constitute a mixed group that was termed “ineligible for treatment” (403 persons in 
total). Possible cases of misclassifications between pre-treatment and ineligible 
groups cannot be ruled out, although the utmost care was taken to reduce the 
problem by manually cross-checking the data with each centre. Mortality rate was not 
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calculated for this group as a whole, as no definite observation time was available. 
Some persons with application status (pre-treatment) between 1 and 365 days 
(included during the final year of observation 2003), may have withdrawn the 
application prior to commencing treatment or been found ineligible, without this being 
captured during data collection, as we have no information about the status of the 
subjects included beyond 31.12. 2003.  
Intention-to-treat in this paper includes every person who ever started on OMT.  
 
Analyses 
Most analyses and descriptive statistics were performed by SPSS version 14.0.2. 
(Inc., Chicago, IL, USA). Mortality rates were calculated per 100 person years, in this 
equivalent case to percentage mortality per year, with 95% confidence intervals. 
A Cox regression with a time-dependent covariate was performed (by SAS 9.2) (SAS 
Institute Inc.), to assess statistical differences between the treatment categories, as 
each individual could have changed status from pre-treatment to treatment and 
subsequently to post-treatment during the observation period. The time-dependent 
covariate was defined according to a subject’s placement within the groups: pre-
treatment, in-treatment and post-treatment. Calculated hazard ratios should be 
interpreted as the relative risk (RR) between groups. 
 
ECG assessment study (Paper 2) 
 
Sample 
The prevalence of QTc prolongation was assessed in a normal clinical setting.  
All OMT patients in Oslo are registered at the Oslo centre, LAR ØST. They are, 
however, mostly treated by GP in collaboration with the social service, and have 
dispensing of OMT medication at pharmacies. This enabled a cross-sectional study 
inviting all patients to have an ECG recording, either at the OMT centre or at the 
pharmacies.  All opioid maintenance treatment patients in Oslo were eligible for the 
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QTc study. An ambulatory team consisting of a medical doctor and a nurse offered 
ECGs at selected pick-up locations for the OMT drugs. These included pharmacies 
and OMT services, where the appointed time of ECG recording was announced by 
posters and hand-outs a week in advance. The recruitment period lasted from 
October 2006 to August 2007. The average number of patients in treatment during 
this period was 976. Two hundred of these, roughly 20 % of the full treatment 
population, were recruited.  
In the sample (n=200), 86.5 % were prescribed methadone and 13.5 % were 
prescribed buprenorphine: 68 % of the patients were men. The methadone patients 
were a few years older than those on buprenorphine and had spent a mean time of 
2.8 years longer in treatment. The sample characteristics were similar to those of the 
broader national sample, based upon data from the Norwegian annual evaluation:83 
in the study period, 30.5 % of the OMT population were women and the mean age of 
the patients was 39.9 years: in Oslo, 82 % of the patients used methadone, while  
18 % were on buprenorphine. The mean daily doses used during the study period 
were 110.2 mg for methadone and 17.3 mg for buprenorphine. 
 
Procedure for QTc measurement 
The patients were approached for an ECG recording between 8 and 10 am, after 
observed intake of their daily dose of OMT drug. When the patients had given verbal 
consent, a 12 lead ECG was recorded. This was done using the same ambulatory 6 
channel ECG- apparatus for all the recordings; Siemens-Elema AB, model: 96 
58 744, serial no: 0165, 50/60 Hz, 200 VA. Each patient was identified by a study 
number. 
QT time was measured in lead V5 in most patients. In a few cases there were 
technical disturbances in V5 and QT time was measured in V4 or V6.  
The cardiologist used a calliper and manually measured the QT and RR intervals of 
five consecutive QRS complexes. The mean values for both the QT and the RR 
intervals were estimated. Based on the mean RR and mean QT, the corrected QT 
(QTc) interval was then calculated by using to the formula of Bazett.86 All the ECGs 
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were examined by the same cardiologist, who was blinded for all patient details, 
including type of OMT medication, as well as dose, age, gender, and time in 
treatment. 
 
Prolonged QTc interval mortality study (Paper 2) 
 
Sample 
In the mortality assessment study, the results from crossing the two different national 
registers in the mortality study were used. The OMT register did not provide 
information on the type of OMT medication that the patients were using. However, at 
the start of the observation period all patients were on methadone and during the 
whole period more than 9 out of 10 patients used methadone, according to the 
annual Norwegian OMT evaluations.82 
 
Analysis 
Deaths were analysed according to time in treatment and cause of death.  
Since cardiac arrhythmia might have been missed, or misdiagnosed for some deaths, 
the estimation of mortality which may have been due to cardiac arrhythmia (and 
hence QTc prolongation) was made by including those deaths in which these causes 
could not be excluded. The overdoses which were confirmed by post-mortem, and 
where fatal levels of various drugs had been detected in the blood, were excluded as 
possible cases of cardiac arrhythmia.  
 
Cardiac and genetic investigations and management study (Paper 3) 
Patients with QTc > 500 msec were identified and recruited from a QTc assessment 
study: ECG was recorded among 200 OMT patients 87, of whom  173 (53 women) 
were on methadone and 27 (9 women) on buprenorphine. The mean age was 41 
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years. The mean daily methadone dose of the sample was 111 mg (standard 
deviation (SD) 35 mg) and buprenorphine dose 19 mg (SD 5 mg). 
The cardiologist, blinded to all patient details, used a calliper and manually measured 
the QT and RR intervals of five consecutive QRS complexes. Based on the mean RR 
and mean QT, the rate-corrected QT (QTc) interval was calculated using the formula 
of Bazett 86. 
A detailed medical history was obtained from patients with QTc interval > 500 msec 
at the initial consultation. Previous cardiac symptoms and disorders were specifically 
requested, as were conditions like HIV, diabetes and liver disorders. All illegal and 
prescribed drugs ever used, particularly those associated with changes in QTc 
interval (e.g. cocaine and methamphetamine, antiarrhythmic, antipsychotic and 
antidepressive medications) were noted. The family history focused on known 
cardiac disorders, symptoms or treatment, sudden death, unexplained deaths or 
accidents, drowning or sudden infant death syndrome.  
Standard dideoxy DNA sequencing was done on blood samples, in accordance with 
the manufacturer’s instructions, using the 3.1 version of the Big Dye terminator cycle 
sequencing kit (Applied Biosystems, Foster City, California, USA). The testing was 
performed at the Department of medical genetics at Oslo University Hospital 
Rikshospitalet, checking for mutations in the following five genes: 
 Potassium channel, voltage-gated, KQT-like subfamily, member 1 (KCNQ1) = 
LQTS1 
 Human ether-a-go-go-related gene (HERG) = LQTS2 
 Sodium channel, voltage-gated, type V, alpha subunit (SCN5A) = LQTS3 
 Minimal potassium ion channel (minK) = LQTS5 
 Minimal potassium ion channel-related peptide 1 (MiRP1) = LQTS6 
 
PolyPhen® software was used to evaluate the pathogenicity of mutations detected 88. 
Serum potassium levels were measured.  
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Patients were encouraged to attend the cardiac outpatient clinic at Oslo University 
Hospital Aker for an appointment with a consultant cardiologist. Investigations 
included ECG at rest, exercise ECG (bicycle) and 24 hours ECG (Holter) recording.  
The final cardiac and genetic investigation and management study would not have 
been possible without the contributions of the cardiology department at Oslo 
University Hospital Aker, who willingly invited the patients to investigations and 
management in their facilities. Oslo University Hospital Rikshospitalet performed the 
genetic testing free of charge, which would otherwise not have been possible given 
our resources.   
 
Ethical approval 
The projects were all approved by the National Committees for Research Ethics and 
by the Data Inspectorate of Norway. 
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Results 
 
Overall findings 
The main findings included a significant overall reduction in mortality risk between 
pre-treatment and in-treatment groups (hazard ratio 0.5, P = 0.001). Following 
treatment, males had significantly higher mortality than the pre-treatment levels.  
Risk for overdose death was significantly reduced with OMT, both for the in-treatment 
group separately and in the intention-to-treat analysis. 
The prevalence of QTc interval above 500 msec was 4.6 % among the methadone 
patients. All the buprenorphine patients had QTc interval within the normal range.  
A dose-dependent association was found between methadone dose and the length 
of the QTc interval in the regression analysis. The maximum mortality rate potentially 
attributable to QTc prolongation was found to be 0.06 deaths per 100 patient years in 
OMT.  
The cardiac investigations of the six patients revealed that QTc intervals fluctuated 
widely over 24 hours and during exercise.  A man and a woman were identified as 
heterozygous carriers of mutations in LQTS1 and LQTS2 genes, respectively.  
The LQTS1 mutation carrier had already switched to buprenorphine and started on 
protective beta-blocker. None of the remaining five patients, including the women 
with the LQTS2 mutation, were willing to switch to buprenorphine or take other 
cardiac protective measures. 
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Results corresponding to the objectives of each paper 
 
Mortality prior to, during and after opioid maintenance treatment (OMT):  
A national prospective cross-registry study 
 
Research objectives: 
 
1. To assess differences in mortality rates prior to, during and after OMT. 
 
The study identified major differences in mortality rates prior to, during and after 
opioid maintenance treatment (OMT); per 100 person years in OMT the estimated 
mortality rates were 2.4 prior to OMT, 1.4 in OMT and 3.4 after OMT. In terms of 
hazard rates for death, there was an overall reduction in mortality risk between the 
pre-treatment and in-treatment groups (hazard ratio 0.5, P = 0.001). The post-
treatment group as a whole was not significantly different from the pre-treatment 
group in regard to mortality. However, following treatment, males had significantly 
higher mortality than the pre-treatment levels. The post-treatment females had a  
non-significant tendency toward reduced mortality.  
 
2. To evaluate mortality reductions in an intention-to-treat perspective. 
 
An overall reduction in mortality risk between the pre-treatment and the intention-to-
treat populations was found, with a hazard ratio of 0.6, P = 0.004. ). In an intention-
to-treat perspective the overdose mortality rate reduction per 100 person years was 
smaller than for the in-treatment group. Still a significant reduction was detected;  
1.9 pre-treatment to 0.7 in the intention-to-treat group. 
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3. To examine the distribution of drug overdose versus non-overdose as 
cause of death. 
 
In terms of overdose mortality, this comprised 79 % of the all pre-treatment deaths 
and 61 % of the all post-treatment deaths. In the in-treatment group, overdose 
mortality accounted for only 27 % of all deaths. In the overall mortality, all groups 
combined, overdose accounted for 53 % of all deaths. A significant reduction in 
overdose mortality rate for the group in OMT (1.4) compared with the pre-treatment 
group (2.4) was found. Overdose mortality rate was particularly prevalent among 
males who had ceased treatment (4.1). 
 
Prevalence and clinical relevance of corrected QT interval prolongation during 
methadone and buprenorphine treatment: A mortality assessment study 
 
Research objectives: 
 
1. To investigate the prevalence of QTc prolongation among opioid maintenance 
treatment (OMT) patients in Oslo. 
 
When investigating the prevalence of QTc prolongation in OMT, we found that  
49.1 % (n=85) of the methadone patients had a QTc interval above 430 msec.  
Fifty patients (28.9 %) had a QTc above 450 msec. There were 15 % (n=16) with a 
QTc interval above 470 msec and 4.6 % (n=8) with a QTc above 500 msec. No 
patients on a dose of less than 120 mg were found to have a QTc above 500 msec. 
All the 27 patients on buprenorphine had QTc levels below 450 msec. 
 
2. To assess any relation between QTc prolongation and type of agonist 
(methadone and buprenorphine), dose, gender and length of treatment. 
 
 A positive correlation was found between QTc interval and dose of methadone, both 
in the univariate (r=0.37, p<0.00) and multivariate analysis (B=0.37, p<0.00).  
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No statistically significant correlation was detected between QTc interval and time in 
treatment, age or gender. No statistically significant association was found between 
buprenorphine dose and the length of QTc interval. 
3. To estimate the extent to which deaths occurring in the Norwegian OMT 
programme might be attributed to QTc prolongation. 
 
The calculation of mortality potentially attributable to QTc prolongation included those 
deaths which were due to overdose and where post-mortem was not conducted, and 
deaths of unknown cause. Based on these figures, the estimated maximum mortality 
theoretically attributable to QTc prolongation was 4 deaths/6450 patient years in 
OMT = 0.06 deaths per 100 patient years in OMT. Only one death occurred that 
could possibly be attributed to cardiac arrhythmia within the first month of treatment. 
This corresponded to 1 death per 3850 OMT initiations. 
 
Opioid maintenance patients with QTc prolongation:  
Congenital long QT syndrome mutation may be a contributing risk factor 
 
Research objectives: 
 
1. To describe the findings of past medical history, drug and family history, 
focusing in particular on cardiac symptoms and other risk factors for QTc 
prolongation. 
 
There were no cases of known HIV, liver disease, diabetes or other chronic 
disorders. No cardiac disorders had been diagnosed. There was no reported use of 
other illegal or prescribed drugs known to affect the QTc interval and no relevant 
family history for any of the participants. Two patients had histories of previous 
cardiac symptoms prior to OMT. 
 
2. To conduct genetic testing for LQTS mutations among OMT patients with QTc 
interval > 500 msec. 
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Of the seven patients tested, two were found to be heterozygous carriers of two 
different LQTS mutations. Both had previously experienced cardiac symptoms prior 
to and during OMT, without receiving further cardiac or genetic investigations.  
One female patient was found to be heterozygous for a mutation in the R885C in 
exon 11 of the Human ether-a-go-go-related gene (HERG), known as LQTS2.  
One male was found to carry a heterozygous mutation in the Q530X of the 
Potassium channel, voltage-gated, KQT-like subfamily, member 1 (KCNQ1) gene, 
known as LQTS1. 
 
3. To discuss in detail the findings from cardiac investigation and management of 
OMT patients found to have QTc prolongation.  
 
The cardiac investigations revealed that QTc intervals fluctuated widely over 24 
hours and during exercise for all patients. Three patients, without LQTS mutations 
detected, had reductions to their QTc interval from above to significantly below 500 
msec with increased heart rate, illustrating the reverse frequency-dependent effect of 
drug-induced QTc prolongation. The LQTS1 mutation carrier had switched to 
buprenorphine and started on a protective beta-blocker. Despite expert advice, none 
of the other patients wanted to switch to buprenorphine, reduce the methadone dose 
or take other cardiac protective measures. 
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Discussion 
 
Cross-register mortality study 
Discussion of results 
This study illustrates reduced mortality during opioid maintenance treatment. It also 
highlights a change in causation, in which overdose mortality is dominant before and 
after treatment, and non-overdose mortality is most common in treatment.  
Our approach enabled calculation of direct risk reductions in OMT in relation to the 
pre-treatment level, demonstrating significant reductions both in overdose deaths 
(RR 0.2) and all-cause mortality (RR 0.5). The mortality reduction may have been 
influenced by the particular characteristics of OMT in Norway at the time. Long term 
opiate addiction was a criterion to be found eligible for OMT. As a consequence, the 
patients admitted to the programme were long term, opioid dependent individuals.  
As the route of heroin administration in Norway is most commonly by injection, these 
were mainly needle users, with correspondingly poor health status.      
The mortality pattern demonstrated in the study resembles findings from other 
studies previously reported in Amsterdam and Stockholm.38;89;90 Although reduced 
from the pre-treatment level, overdose mortality was still found in treatment.  
Our overdose mortality rate during treatment (0.4 per 100 person years) is similar to 
what has been reported by Caplehorn et al, who identified an overdose mortality of 
0.5 per 100 person years during treatment.91 It is reasonable to assume that these 
overdoses were caused by polydrug intoxications, in which illicit opiates may or may 
not have been involved. Unfortunately, the registers did not provide any information 
on the OMT drug and dose the patients who died of overdose during treatment were 
on.  
Another noteworthy finding is that non-overdose deaths in the in-treatment group 
were dominating. Somatic health problems promoted swift acceptance into the 
programme. However, the cross-register data did not provide information on the 
health status of each individual patient. Exact figures for HIV prevalence in the study 
population were therefore unavailable in the dataset, but it is known to be relatively 
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low in Norway.92 Estimated HIV prevalence based on available information, was in 
the range of 2–5 % among Norwegian OMT patients during the study period. 
In addition to these findings, the study also demonstrated that a significant mortality 
risk reduction was found using the intention-to-treat perspective; in which mortality in 
drop outs was also included. In this perspective the overall mortality RR was 0.6 
compared with the pre-treatment level. The benefits of OMT were supported also 
from the intention-to-treat perspective. However, as expected the benefit was less 
than when compared with the reduction found in the in-treatment group.  
Studies focusing only on treatment results for completers will tend to overestimate 
the positive outcomes of OMT due to selection mechanisms. By including all patients 
who ever started on OMT in an intention-to-treat analysis, this selection bias can be 
ruled out. 
The increase in mortality for the post-treatment group was mainly caused by an 
increased frequency of overdose deaths, corresponding with previous findings.9;29 
Patterns of mortality and mortality reductions were generally similar for both genders, 
with a couple of notable exceptions. Men who ceased OMT treatment had twice the 
risk of death as women in the same situation. The increase in overdose mortality 
post-treatment was more or less confined to males. Unfortunately, the dataset did not 
give information with regards to why individuals had stopped OMT, and whether this 
was voluntary or not. Thus, we have no data to provide an explanation for this 
gender-related pattern. However, males in the general population also appear to 
have about twice the age-adjusted mortality risk as females.84 It is possible that the 
post-treatment group included individuals with the largest burden of psychiatric 
comorbidity, since it is generally accepted that it is the most heavily burdened and 
non-compliant patients who leave OMT.30;38;93;94 
After the conductance of our study, Clausen and colleagues did further analyses of 
the cross-register data generated.95 Mortality aspects among opioid users in relation 
to opioid maintenance treatment, age and causes of death were investigated.  
They found that overdose deaths among all age groups were reduced during OMT. 
Whilst in treatment, older patients (≥50 years of age) were at higher risk for both 
somatic and traumatic deaths compared with the younger, and in general, deaths 
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during OMT were likely to be due to somatic causes. Before entering treatment, 
younger patients (≤ 34 years of age) had a greater risk of fatal overdose.  
After leaving treatment, it was the older patients (≥ 50 years of age) who faced the 
greatest risk of dying from an overdose. A recently published British paper, 
retrospectively investigated factors associated with mortality during methadone 
maintenance treatment for 2378 patients.96 Overuse of methadone, a history of 
psychiatric admissions and comorbidity were all associated with increase in all cause 
mortality. More specifically, history of psychiatric admission, as well as previously 
been prescribed benzodiazepines, were found to be risk factors for drug dependent 
death. Fareed et al looked at chronic conditions as risk factors for premature death 
among older heroin addicts on MMT.97 Diabetes mellitus, liver and gastrointestinal 
cancers were found to be associated with increased mortality. However, patients who 
remained in treatment showed significant improvement related to drug use, 
psychiatric, medical and legal problems compared to those who dropped out.    
In the cross-register study, we did not exhibit information on the OMT drug the 
patients were on. More recent studies have investigated differences between 
methadone and buprenorphine maintenance treatment with regards to mortality.  
Bell and his colleagues published two large cross-register studies in 2009. In the first 
of these studies, they compared retention in OMT and mortality after initial entry to 
either methadone or buprenorphine treatment.98 During induction, the risk of death 
was found to be lower with buprenorphine than methadone. The overall risk of death 
was lowest during treatment and significantly higher during the first 12 months after 
leaving both methadone and buprenorphine treatment. In the second paper, they 
looked at the risk of overdose whilst in OMT.99 This study involved 13 718 patients on 
methadone and 2716 on buprenorphine. The main finding was that the risk of 
overdose death per thousand people in treatment was higher for methadone than 
buprenorphine (RR 4.25).  
A Cochrane review published in 2009 by Mattick et al investigated methadone 
maintenance therapy (MMT) versus no opioid replacement therapy for opioid 
dependence.100 They included 11 randomised clinical trials (RCTs), of which two 
were double-blind. The review concluded that MMT appeared statistically more 
effective on retaining patients in treatment and in suppressing heroin use.  
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However, they did not find significant differences in criminal activity or mortality. As 
mentioned in the introduction, RCTs may not be the most suitable design to study 
long-term effects of OMT on mortality, due to ethical aspects, as well as small 
number of participants and short follow-up periods. A recently published large 
Australian cross-register study involved 42 676 people entering OMT between 1985 
and 2006.101 The researchers here concluded that mortality was higher out of 
treatment than in, particularly during the first weeks out of OMT. During induction to 
treatment, mortality was elevated for methadone but not for buprenorphine, 
supporting the results of Bell et al. Compared to out of treatment, the overall mortality 
in treatment was reduced regardless of whether patients were receiving methadone 
or buprenorphine. Across the entire cohort, OMT was estimated to produce a 29% 
reduction in mortality. 
 
Methodological considerations 
The cross-register approach chosen in this study allowed for investigation of mortality 
differences prior to, during and post OMT, including an intention-to-treat perspective. 
It also enabled the separation of overall mortality into overdose and somatic mortality 
within the different groups. The use of intention-to-treat in this area of research may 
be regarded controversial. OMT is often considered to be a life long treatment.  
This does not, however, necessarily justify exclusion of mortality in treatment 
dropouts when estimating the benefits. Leakage of OMT drugs from the programme 
to persons outside OMT is a well-recognised problem that needs to be counteracted. 
Mortality reduction in treatment is therefore only one of several goals in an OMT 
programme, and has to be weighed against other issues. This underlines the 
importance of knowing the potential in reducing mortality risk for an entire population 
of opioid addicts eligible for OMT, not only those currently in treatment. 
Cross-register studies are rational and efficient in evaluating mortality and other 
aspects of OMT. However, there are currently only a few countries, mostly 
Scandinavian, where such national registers exist and are feasible for this approach. 
The high quality of the data from the death register in Norway adds strength to our 
study. However, it is important to note that the mortality cause is dependent on the 
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individual practice of the doctor submitting the death certificate.  
Misclassification of a true suicide as overdose would tend to cause overestimation of 
overdose as a cause of death. A limitation to the dataset is the lack of information 
about individual type of maintenance drug or dose. During the observation period for 
this study, methadone was the most widely used medication, whereas buprenorphine 
introduced in 2001 was used by 23% by the end of 2003. Additionally, no information 
on the subjects’ drug use history was available, nor whether termination of treatment 
was voluntary or not. The relatively high age of the cohort may be explained by the 
age limit of 25 years. Notably, age was measured at the end of the observation time, 
not at inclusion.  
Register-based studies are clearly dependent on the quality of the registers 
employed. In this study, the national OMT patient register was based on electronic 
patient records information from the regional OMT centres. For patients in treatment 
and for the post-treatment group, we believe that the information is up to date and of 
good quality, as budgets and monitoring of expenses are based on continuously 
updating the data. Despite thorough control of each individual that did not enter 
treatment (ineligible), some cases might wrongly have been classified as belonging to 
the pre-treatment group. Since the ineligible for treatment group had a low crude 
mortality rate, misclassifications could deflate mortality rates for the pre-treatment 
group. As the issue were thoroughly examined and manually checked, we find it 
unlikely that results were significantly affected.   
The study population represents those who were found eligible to OMT in Norway 
during the study period. At the time this comprised between 1/3 and ½ of all injecting 
opioid dependants in Norway, characterised by a long-term and severe opioid 
dependence syndrome. As OMT programmes vary internationally in terms of different 
inclusion policy, availability and capacity, this will affect the degree to which the 
results apply to populations in other nations. The absolute levels of mortality 
reduction will vary accordingly across various populations. We believe that the 
relative level of risk reduction of mortality as a result of OMT is more comparable 
between different study groups, than the absolute mortality levels are.   
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ECG assessment study 
Discussion of results 
Eight of the 173 methadone maintenance patients (4.6 %) had an unequivocally 
prolonged QTc time above 500 msec, which placed them at increased risk of cardiac 
arrhythmia and TdP.43 Methadone dose was found to be positively related to QTc 
prolongation, and all of the eight cases of with QTc prolongation greater than 500 
msec were patients receiving methadone doses of 120 mg or more. The finding of a 
dose-dependent relationship between methadone and QTc prolongation points to 
causality and is consistent with results previously reported in other studies.56;58  
No association was found between the QTc prolongation and age. We hypothesised 
that it was possible that the amount of time spent in methadone treatment might have 
had a cumulative effect on the QTc interval, but no such association was detected.  
In other studies, women have been found to be at greater risk for QTc prolongation 
than men.102;103 We did not detect such a difference.  
An Australian study looked at the QTc interval of OMT maintained subjects on 
moderate doses; n = 35 with mean daily methadone dose 69 mg (standard deviation 
+/- 29 mg) and n= 19 with mean daily buprenorphine dose 11 mg (standard deviation 
+/- 5 mg).104 Despite methadone users having a longer QTc interval than the 
buprenorphine users, these were all well below 500 msec. They subsequently 
concluded that methadone and buprenorphine at commonly used daily doses remain 
safe agents for OMT. A study by Krantz investigated the QTc interval changes at 
baseline and 6 months after methadone induction.105 The results highlighted the 
heterogeneity of QTc interval changes, where subjects exceeding 500 msec 
increased from 0 % to 2 %. Fonseca and colleagues performed a cross-sectional 
study among 109 methadone maintained subjects.106 They found that 1.8 % 
exhibited a QTc interval above 500 msec and this was associated with higher daily 
methadone dose (median 120 mg). A dose-dependent correlation was observed.  
In terms of plasma concentrations, no association was found between plasma 
concentration of (R)-methadone and (S)-methadone and the length of the QTc 
interval. However, a recently published study separated (R,S)-methadone into (R)- 
and (S)-methadone, and looked at the two components effect on the QTc interval.107 
(R)-methadone mainly mediates the opioid effect, whereas (S)-methadone is a more 
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potent blocker of the HERG potassium channel, which can cause QTc prolongation. 
They found that substituting (R,S)-methadone with (R)-methadone significantly 
reduced the length of the QTc interval. 
 
Methodological considerations 
In this study we used a cross-sectional approach. All the information was therefore 
gathered at the same time, as opposed to a cohort study, which follows individuals 
over time. The cross-sectional approach is not associated with the many difficulties 
affecting other designs, such as loss to follow-up and recall bias. There are, however, 
some problems associated with this type of study.108 Sample selection must be 
considered. Often the interpretation of results is extended widely, despite research 
being carried out on a limited number of subjects. As the validity of the extrapolation 
depends on the representativeness of the sample, a random selection of individuals 
is the ideal method. Another problem faced by this approach is linked to the response 
rate, and indeed volunteer bias may occur. This is particularly well-recognised when 
surveys are distributed by post. In any study efforts should be made to increase the 
response rate as much as possible. Finally, the problem of cause or effect might 
occur with cross-sectional designs. Some case-control studies face similar problems, 
and a prospective study is the ideal way to investigate causation.     
The final sample included approximately 20 % of the Oslo OMT population, which did 
not differ in characteristics from the OMT population of Oslo as a whole.  
Most patients asked to participate appeared keen to have their heart checked and 
there were less than 10% who declined participation. We do not have any data on 
these individuals, but there was little to suggest from our observations that these 
were any different from the ones who participated. The external validity of our 
findings therefore seems well maintained. 
A limitation associated with our data is the lack of additional information regarding the 
patients’ concomitant use of illegal substances. The ability of cocaine to acutely 
prolong the QTc interval was recognised many years ago.109 More recent studies 
have supported this finding.110;111 Similarly, Haning and Goebert demonstrated QTc 
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prolongation at an abnormally high rate among methamphetamine dependents.112  
It is worth noting that, according to the Norwegian annual evaluations, in our sample 
and in the Norwegian OMT population as a whole, the use of cocaine and/or 
methamphetamine was close to non-existent, both in the QTc study period83 and the 
mortality assessment period.82 Another limitation of this study is that we do not have 
information about the nutritional status and life conditions of the patients in our 
sample, and severe malnutrition with hypokalemia can give rise to prolongation of the 
QTc interval.113 Also, in the QTc assessment study the number of patients on 
buprenorphine was low (n=27). This makes it difficult to compare the two OMT drugs 
and to draw any firm conclusions with regards to the cardiac properties of 
buprenorphine. It adds strength to our study that all the ECGs were examined by the 
same cardiologist, who was blinded for all patient details, including type of OMT 
medication, as well as dose, age, gender, and time in treatment. 
 
Prolonged QTc interval mortality study 
Discussion of results 
The estimated mortality potentially attributable to QTc prolongation was 0.06 deaths 
per 100 patient OMT years. The results also show that only one unexplained death 
occurred during the first month of OMT, which gave a figure of 1 death per 3850 OMT 
initiations. To our knowledge, this is the first attempt to estimate the potential impact 
on mortality from QTc prolongation in a large, national sample of OMT patients. 
These calculations add important information to the field as they indicate that the 
extent to which methadone gives rise to ventricular arrhythmias resulting in sudden 
death in OMT appears extremely low. 
 
Methodological considerations 
This study used the same data from the cross-register mortality study. The strengths 
stemming from large numbers in complete national registers therefore apply. 
Nevertheless, the potential mortality attributable to QTc prolongation should be 
interpreted with caution. It is an important point methodologically that only about one 
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third of the death certificates were supplemented with information supported by 
autopsy and toxicological analyses, hence the other 2/3 of cases are based on 
“external” examinations with the risk of misclassification. Deaths among patients with 
a known history of opiate addiction may well be misclassified as overdose rather than 
for example suicides or sudden cardiac deaths, as previously discussed by Gossop 
et al.7 The mortality estimation was made by including the two cases of overdose 
without post-mortem and the two deaths of unknown cause. It is possible that not all 
of these four cases occurred as a result of ventricular arrhythmia associated with 
methadone, and in that case, the estimate of 0.06 deaths per 100 patient OMT years 
would represent an overestimation of the actual impact of QTc prolongation on 
mortality. Similarly, potential misclassification of the cause of death could also involve 
the deaths not included in the calculation. We have no information indicating 
differential classification between the outcome groups. In the absence of any 
evidence to support this, we believe that this is unlikely to have introduced any 
substantial bias into our reported calculation of mortality. Another limitation to this 
prolonged QTc interval mortality estimation is that the dataset did not provide 
relevant information on somatic health status, concurrent drug use or type of OMT 
drug and dose for the group in treatment.  
 
Cardiac and genetic investigations and management study 
Discussion of results 
The main findings of this study involved identification of two heterozygous LQTS 
mutations carriers. QTc intervals fluctuated widely over 24 hours and during exercise 
for all the patients, ranging from below 500 msec to above 600 msec. Only one 
patient switched to buprenorphine and started on a beta blocker. None of the other 
patients wanted to switch to buprenorphine or take other cardiac protective 
measures. 
To our knowledge, this is the first study to identify LQTS mutation as a potential pre-
existing and contributing risk factor of QTc prolongation in OMT patients. Among the 
seven patients with QTc prolongation tested for LQTS, two heterozygous mutation 
carriers were identified. Both had previously experienced cardiac symptoms prior to 
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and during OMT. However, neither of the patients had ever had their QTc interval 
measured or had other cardiac investigations prior to the study. Family history did not 
prove a useful marker of mutation status, as it was negative for both patients.  
No other risk factors for QTc prolongation were identified.  
The results of the cardiac investigations illustrate the diurnal fluctuations of the QTc 
interval. 114  In this study we recorded 24 hour ECGs, in which QTc intervals varied 
between markedly prolonged to below or down to 500 msec for all of the six patients. 
The exercise test further indicated the changes in QTc interval that can occur with 
increased heart rate. 115 Three patients without LQTS mutations detected, had 
reductions to their QTc interval from above to significantly below 500 msec with 
increased heart rate, illustrating the reverse frequency-dependent effect of drug-
induced QTc prolongation. 116  
One male was found to carry a heterozygous mutation in the KCNQ1 gene, known as 
LQTS1. He had earlier suffered two cardiac arrests requiring resuscitation during 
heroin withdrawal. Without knowledge of his genetic condition, he had switched to 
buprenorphine prior to the cardiac outpatient appointment. During the 24 hour tape 
recoding, the QTc interval fluctuated between normal values of 444 msec up to 601 
msec at maximum heart rate. LQTS1 has been found to be more sensitive than 
LQTS2 and LQTS3 to sympathetic stimulation. 71 The underlying LQTS1 mutation, in 
combination with extreme stimulation of the sympathetic nervous system during 
heroin withdrawal, may have triggered the two episodes of cardiac arrest. As this 
resting QTc interval was normal on buprenorphine, it is uncertain whether the 
patient’s genetic mutation would have been detected if he had not been treated with 
methadone when participating in the original study. Hinterseer et al has recently 
shown that increased short-term variability of QT interval of > 4.9 msec has a 
sensitivity of 83 % and specificity of 68 % in identifying new LQTS mutation carriers 
in people with a normal QTc interval. 117 They concluded that this non-invasive 
investigation could form a marker for diagnostic screening before results of genetic 
testing are available. 
Clinical managerial issues were highlighted in this study. Only the patient with LQTS1 
mutation, who already had switched to buprenorphine, was willing to take a  
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beta-blocker. None of the other patients wanted to switch to buprenorphine, reduce 
the methadone dose or take other cardiac protective measures, despite thorough 
information and strong medical advice. The cardiac symptoms experienced over 
many years by the two LQTS mutation carriers, highlights the importance of history 
taking prior to OMT.  
 
Methodological considerations 
The number of participants in this study was low. However, the identification of these 
patients required recruiting from a QTc assessment study with a much larger sample 
of 200 OMT patients, as the prevalence of QTc interval > 500 msec found to be  
4.6 % among methadone maintained patients.87 Given the nature of OMT in Oslo, the 
goal of reaching 200 OMT patients and recording their ECGs was satisfactorily 
achieved by stretching our resources.  
This study is limited by the reduced sensitivity of a single ECG recording. Research 
has shown that 10-36 % of heterozygous mutation carriers are silent carriers and 
have a normal QTc interval on their ECG.118 Consequently, there may have been 
missed cases of LQTS mutations among the remaining 165 methadone and 27 
buprenorphine patients with QTc intervals < 500 msec in the QTc assessment study. 
This is indicated by the fact that the patient with the LQTS1 mutation exhibited a 
normal QTc interval at rest after switching from methadone to buprenorphine.  
Finally, even in patients referred for genetic testing following the most stringent 
criteria, a mutation is identified in approximately 70 % of the cases.119;120 It implies 
that a substantial proportion of LQTS mutations have not yet been discovered and 
are subsequently not tested for.71 In the future, it is expected that more mutations in 
LQTS candidate genes will be detected. 
 
Ethical considerations in the research 
In all research involving humans, ethical considerations safeguarding the subjects 
involved must be incorporated during the planning and conduction of a study.  
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Opioid dependent individuals form a particularly vulnerable group, which are often 
found to be in an exposed situation with increased prevalence of somatic diseases 
and mental illness.10 Their need for treatment and desire for change are often 
substantial, but this may at the same time leave them more easily exposed to exploit. 
It is therefore crucial to base the treatment offered on evidence from research, with 
knowledge of associated risk factors and outcome. The cross-register mortality study 
is ethically important, as is yields information on OMT on crude measures of mortality 
and overdose prior to, during and after treatment. As a cross-register approach was 
used, this study did not involve any type of intervention for the patients.  
In the ECG assessment study the patients were approached for participation after 
being thoroughly informed about the purpose of the ECG recording. The aspect of 
voluntary participation was emphasised and patients had to give informed consent 
before participating. The finding of a very low mortality rate that could potentially be 
attributable to QTc prolongation in OMT, was clinically important and confirms that 
patients are not being put on a treatment which itself carries a high mortality risk.  
In the final study the same approach with informed consent was practiced.  
Patients who decided to participate received cardiac and genetic investigations and 
were offered professional cardiac management based on findings by a senior 
cardiology consultant.  
  
Implications for policy and treatment 
The main finding of decreased mortality for patients in OMT compared to the period 
prior to and after treatment clearly has implications for OMT policy. The increased 
mortality, and particularly overdose rate, following treatment should warrant caution 
with regards to involuntary ending OMT. As death from somatic causes was most 
common whilst in treatment, this should be an indicator of the burden of somatic 
illnesses these patients carry. OMT provides an opportunity to address these 
problems, for a group of patients who otherwise rarely seek the help of health 
professionals. As of 2010 new guidelines for OMT have been implemented in 
Norway.121 Compared to the previous guidelines, the age requirement has now been 
removed and although OMT should as a general rule not be the first treatment of 
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choice, failed attempts at abstinence-oriented treatment are no longer a requirement. 
Continuous drug-use or general lack of compliance with treatment requirements is 
not alone a satisfactory reason for involuntary eviction from OMT.  
Our estimations indicate that the maximum mortality attributable to QTc prolongation 
and ventricular arrhythmia in opioid maintenance treatment is very low, despite a 
prevalence of QTc interval above 500 msec of nearly 5 % among methadone patients 
and indications of a dose-dependent relation.87 Agreement on safe and rational 
cardiac management of methadone patients has so far proven contentious.  
In Norway this discussion was raised in 2007 in the Journal of the Norwegian Medical 
Association by two general practitioners, who claimed that QTc prolongation due to 
methadone could be a cause of sudden cardiac deaths in OMT.122 They advocated 
ECG screening prior to initiation of methadone maintenance treatment. After a review 
of the evidence based literature on this topic, an expert team recommended instead 
that ECG should be recorded during treatment and particularly if there were other risk 
factors for QTc prolongation present.123 This was largely based on research done by 
Krantz, who was one of the first cardiologists to describe the phenomenon. Annals of 
internal medicine published in 2009 new recommendations by a team of researchers 
and clinicians, including the same Krantz. This time advocating a pre-treatment ECG, 
a follow-up ECG within 30 days and then annually.124 At present, however, there are 
no widely accepted guidelines, and views regarding ECG screening are conflicting.69  
Our findings do not point to ECG recording prior to OMT as a life-saving,  
cost-beneficial screening program. Rather, in the absence of firm guidelines, we 
suggest a practical approach for clinicians. A past medical history, focused 
particularly on cardiac symptoms and disorders, should always be obtained prior to 
treatment with methadone. If indicated by the history or in the presence of other 
known risk factors for QTc prolongation, the drug of choice is primarily 
buprenorphine. The patient should not be started on methadone without cardiac 
protection. An ECG, preferably over 24 hours, should be recorded at this stage. If this 
reveals QTc prolongation, the patients should be referred for genetic testing if 
available, along the same referral criteria as any other individual with similar findings. 
Further research should aim to clarify the costs and benefits of ECG screening in 
OMT prior to potential implementation. 
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Opioid maintenance patients with QTc prolongation:  
Congenital long QT syndrome mutation may be a contributing risk factor 
 
Objectives 
This study investigates opioid maintenance treatment (OMT) patients found to have corrected 
QT (QTc) interval above 500 msec, with particular focus on past medical history, genetic 
testing and cardiac investigations. 
 
Methods 
Detailed medical and cardiac history was obtained, with particular focus upon risk factors.  
Cardiac investigations, including genetic testing for the five most common long QT 
syndrome (LQTS) mutations, exercise electrocardiography (ECG) and 24-hour ECG 
recordings, were performed. 
 
Results 
Of 200 OMT patients assessed with ECG, seven methadone maintained patients identified 
with QTc interval above 500 msec participated in this study. Two were identified as 
heterozygous LQTS mutations carriers. Both had experienced cardiac symptoms prior to and 
during OMT. No other risk factors for QTc prolongation were detected among the seven 
patients. Six of the seven patients underwent further cardiac investigations. QTc intervals 
fluctuated widely over 24 hours and during exercise for all patients. Only one of the LQTS 
mutation carriers switched to buprenorphine and started on a beta blocker. Despite strong 
medical advice and information, none of the other patients wanted to switch to buprenorphine 
or take other cardiac protective measures. 
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Conclusion 
Findings indicate the importance of recording a thorough past medical history, focusing 
specifically on previous cardiac symptoms, and on other known risk factors for QTc 
prolongation, prior to initiating patients on methadone.  
 
Keywords 
Congenital long QT syndrome, genetic, management, methadone, QT prolongation  
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Opioid maintenance patients with QTc prolongation:  
Congenital long QT syndrome mutation may be a contributing risk factor 
 
Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H. 
 
1. Introduction 
The association between methadone and prolongation of the corrected QT (QTc) interval is 
well-established (Fonseca et al., 2009; Peles et al., 2007; Wedam et al., 2007). QTc 
prolongation is characterised by abnormal T-wave morphology seen on electrocardiogram 
(ECG) and is in itself asymptomatic. It is associated with torsades de pointes (TdP), which is 
often self-terminating and may cause a quick syncopal episode. If TdP is more persistent, 
ventricular fibrillation leading to cardiac arrest and sudden death can result (Vincent, 2000). 
As TdP rarely occurs with a QTc interval of less than 500 msec, this is generally considered 
the threshold of risk for TdP (Priori et al., 2003). 
 
Drug-induced QTc prolongation is caused mainly by blockade of the slow component of the 
delayed rectifier K+ current (IKr), a major repolarisation current in the heart. IKr blockers, such 
as methadone, increase the dispersion in repolarisation. They often display a reverse 
frequency-dependent effect, in which the degree of QTc prolongation is more prominent 
during slow heart rates (Chiang, 2004). A dose-response association between methadone and 
the QTc interval has been found, with increased dose associated with a higher frequency of 
reported syncope (Fanoe et al., 2007).  
 
Multiple risk factors may contribute to QTc prolongation, including hepatic cytochrome P450 
inhibitors, structural heart disease and hypokalemia, as well as genetic predisposition 
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(Chiang, 2004; Reddy et al., 2010). Three major genes involved in congenital long QT 
syndrome (LQTS) were identified in 1995 (De Ferrari & Schwartz, 2009).  Most mutations 
occur in LQTS1, LQTS2 and LQTS3 genes (Markiewicz-Loskot et al., 2009). A study tested 
for mutations in the LQTS1, LQTS2, LQTS3, LQTS5 and LQTS6 genes, which all code for 
subunits of cardiac ion channels. The overall prevalence in the general population of 
heterozygous mutation carriers for the five genes was estimated to be between 1/100 and 
1/300 (Berge et al., 2008). 
 
Phenotypically silent or subclinical LQTS mutation carriers may become symptomatic in the 
presence of other risk factors (Chiang, 2004), including drugs with QTc prolonging properties 
such as methadone. However, the LQTS carrier status is often unknown to the individual and 
clinician prior to the risk exposure and subsequent clinical manifestation (Goldenberg & 
Moss, 2008). This study is a case series of OMT patients with QTc interval above 500 msec. 
A detailed medical and cardiac history was obtained, with particular focus upon risk factors.  
Cardiac investigations, including genetic testing for the five most common LQTS mutations, 
were performed. 
 
2. Materials and methods 
Patients with QTc > 500 msec were identified and recruited from a QTc assessment study: 
ECG was recorded among 200 OMT patients (Anchersen et al., 2009), of whom  173  were 
on methadone and 27 on buprenorphine. The mean age was 41 years. The mean daily 
methadone dose was 111 mg and buprenorphine dose 19 mg. 
 
A medical history was obtained from patients with QTc interval > 500 msec at the initial 
consultation. Previous cardiac symptoms and disorders were specifically requested. All 
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substances (including alcohol) and medications ever used, particularly those associated with 
changes in QTc interval were noted. The family history focused on known cardiac disorders, 
symptoms and treatment.  
 
Standard dideoxy DNA sequencing was done on blood samples, using the Big Dye terminator 
cycle sequencing kit. Testing was performed at the Department of medical genetics at Oslo 
University Hospital, checking for mutations in the following five genes: 
 Potassium channel, voltage-gated, KQT-like subfamily, member 1 (KCNQ1) = 
LQTS1 
 Human ether-a-go-go-related gene (HERG) = LQTS2 
 Sodium channel, voltage-gated, type V, alpha subunit (SCN5A) = LQTS3 
 Minimal potassium ion channel (minK) = LQTS5 
 Minimal potassium ion channel-related peptide 1 (MiRP1) = LQTS6 
 
Patients were encouraged to attend the cardiac outpatient clinic at Oslo University Hospital 
for an appointment with a consultant cardiologist. Investigations included ECG at rest, 
exercise ECG (bicycle) and 24-hour ECG recording.  
 
The study was approved by the Regional ethics committee. 
 
3. Results 
Among the 200 OMT patients, eight methadone patients were identified with QTc >500 
msec. One declined participation and was not included in this study. Seven patients (one 
woman, 6 men) attended the initial appointment, where a full medical history was obtained 
and blood tests for potassium level and genetic testing for LQTS mutations performed.  
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//Table 1//  
 
Participants were aged 29 -53 years (mean 40.8 years). Daily methadone doses were 120-240 
mg. Initial QTc ranged from 507-579 msec. All seven patients had normal serum potassium 
levels. Genetic testing revealed two heterozygous mutations for LQTS: both patients had 
histories of previous cardiac symptoms. No cardiac disorders had been diagnosed. There were 
no cases of known HIV, liver disease, diabetes or other chronic disorders. There was no 
reported use of other drugs known to affect the QTc interval and no relevant family history. 
 
//Table 2// 
 
Patient 7 dropped out of OMT after the initial appointment and testing. He did not undergo 
cardiac investigations and is excluded in further results. The remaining six patients received 
additional investigations. Patient 1 had a normal QTc at rest (444 msec). This increased to 
535 msec on the exercise test and varied between 480-560 msec on the 24-hour recording. 
The other three patients without detected mutations had QTc intervals at rest >500 msec. The 
QTc interval of these three patients fell substantially <500 msec on the exercise test (460-477 
msec). During the 24-hour recording, these patients had peaks >500 msec.  
 
3.1. Patient with LQTS2 mutation 
This patient was a 32 year old woman with longstanding injecting heroin use, until admitted 
to OMT 2 years previously when she was started on methadone. On the initial ECG 
recording, QTc was 532 msec. She received 120 mg of methadone/day. Genetic testing 
revealed that the patient was heterozygous for the LQTS2 mutation.  
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In her medical history, she described 5-6 episodes of syncope and daily episodes of dizziness, 
without palpitations. She had never consulted medical staff for this problem. Resting QTc 
interval was 501 msec. During exercise, heart rate reached a maximum of 138 bpm, while 
blood pressure remained unchanged at 93/78 mmHg. She had to stop after 4 minutes due to 
exhaustion. There was no chest pain or dizziness during the investigation and ECG showed 
no signs of arrhythmia or ischemia. QTc during the investigation increased to 507 msec. 
During the 24-hour recording QTc interval varied between 500-560 msec. 
 
The patient did not wish to switch to buprenorphine. She declined to start on a protective 
beta-blocker or reduce the methadone dose. Finally, she turned down the offer of an 
implantable cardiac rhythm recorder.  
 
3.2. Patient with LQTS1 mutation 
This patient was a 30 year old man with longstanding injecting heroin use until admitted to 
OMT 4 years before the study. He was receiving 120 mg methadone/day. On the initial ECG, 
QTc was 513 msec. Genetic testing detected a heterozygous LQTS1 mutation. 
 
After the prolonged QTc was detected, he requested transfer from methadone to 
buprenorphine. At the cardiac outpatient appointment he appeared in good health. His past 
medical history indicated two separate episodes of cardiac arrest prior to OMT: both occurred 
during withdrawal from heroin and required resuscitation. He had since experienced 3-4 
episodes of syncope. Two years ago he had an episode of loss of consciousness resulting in 
hospital admission. He was discharged without any diagnosis or medication. QTc interval 
was not investigated at that time.  
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For resting ECG, the QTc was 441 msec. During exercise, heart rate reached a maximum of 
138 bpm; blood pressure reached 142/78 mmHg. He was moderately out of breath at the end, 
but did not experience chest pain or dizziness. There were no signs of arrhythmia or ischemia 
on his ECG. QTc during the investigation remained unchanged. The 24-hour ECG recording 
revealed fluctuations of QTc between 444 msec at lowest heart rate up to 601 at maximum 
heart rate.  
 
As the patient had already switched to buprenorphine, he was advised to start on a 
prophylactic beta-blocker based on his medical history, LQTS1 mutation and the 24 hour 
ECG recordings. He accepted this and was prescribed 50 mg metoprolol (Selo-Zok®) daily. 
The cardiologist also raised the possibility of an implantable cardiac rhythm recorder, which 
he declined.  
 
3.3. Patients without LQTS mutations 
The remaining four patients received individual follow-up appointments. One patient had 
experienced three non-specific episodes of loss of consciousness over the last 20 years, which 
were uncertain in origin. As no causation of QTc prolongation beyond methadone was 
established, these patients were advised to switch to buprenorphine, which all patients 
declined. They were recommended reduction of methadone dose, or alternatively a beta-
blocker. These offers were also declined: all patients stated that they wished to continue the 
current methadone treatment. Finally, they were offered a small implantable cardiac rhythm 
recorder. No patient opted for this device. After information about possible risks, these 
patients chose to continue on the same methadone dose, without preventative measures. 
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4. Discussion 
In this study we recorded 24-hour ECGs, in which QTc varied between markedly prolonged 
to 500 msec or less for all the patients. The exercise test further indicated the changes in QTc 
interval that can occur with increased heart rate (Extramiana et al., 2009). Results of our 
cardiac investigations illustrate diurnal fluctuations of the QTc interval (Harris & Steare, 
2006) . Three patients without LQTS mutations detected, had reductions to their QTc interval 
from above to significantly below 500 msec with increased heart rate, illustrating the reverse 
frequency-dependent effect of drug-induced QTc prolongation (Chiang, 2004).  
 
The study identified two heterozygous LQTS mutations carriers. The cardiac symptoms 
experienced over many years by these two patients, highlight the importance of history taking 
prior to OMT. Family history did not prove a useful marker of mutation status, as it was 
negative for both patients. No other risk factors for QTc prolongation were identified. Only 
one patient already on buprenorphine started on a beta blocker. None of the other patients 
wanted to switch to buprenorphine or take other cardiac protective measures. 
 
One male was found to carry a heterozygous LQTS1 mutation. He had earlier suffered two 
cardiac arrests requiring resuscitation during heroin withdrawal. He had switched to 
buprenorphine prior to the cardiac outpatient appointment. During the 24-hour tape 
recording, the QTc interval fluctuated between normal values of 444 msec and 601 msec at 
maximum heart rate. LQTS1 has been found to be more sensitive than LQTS2 and LQTS3 to 
sympathetic stimulation (Markiewicz-Loskot et al., 2009). The underlying LQTS1 mutation, 
in combination with extreme stimulation of the sympathetic nervous system during heroin 
withdrawal, may have triggered the two episodes of cardiac arrest. It is uncertain whether the 
patient’s genetic mutation would have been detected if he had not been treated with 
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methadone when participating in the original study. Increased short-term variability of QT 
interval of > 4.9 msec has recently been found to have a sensitivity of 83 % and specificity of 
68 % in identifying new LQTS mutation carriers in people with a normal QTc interval 
(Hinterseer et al., 2009). 
 
The marked diurnal fluctuations of the QTc interval among the patients clearly limit the 
reliability of a single ECG used for identification. Additionally, between 10-36 % of 
heterozygous mutation carriers are silent carriers and have a normal QTc interval on their 
ECG (Priori et al., 2003). Consequently, there may have been missed cases of LQTS 
mutations among the remaining 192 patients with QTc intervals < 500 msec in the QTc 
assessment study: it can not be excluded that the prevalence of LQTS mutations is the same 
in this group. Finally, even in patients referred for genetic testing following the most stringent 
criteria, a mutation is identified in approximately 70 % of the cases (Goldenberg & Moss, 
2008; Napolitano et al., 2005). This implies that a substantial proportion of LQTS mutations 
have not yet been discovered and were subsequently not tested for. Further studies, including 
24-hour ECGs and genetic testing, are needed in order to investigate the prevalence of QTc 
prolongation and associated risk factors among methadone maintained patients in more detail.  
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